

**Supplementary Table 2. Population characteristics by etiology**

	ALD (n=82)	Viral hepatitis (n=512)	NAFLD (n=132)	Cholestatic/AIH (n=29)	Other/Cryptogenic (n=60)	Overall (n=816)	P-value
Sex							
Female	17 (20.7)	252 (49.2)	62 (47.0)	18 (62.1)	27 (44.3)	376 (46.1)	<0.001
Male	65 (79.3)	260 (50.8)	70 (53.0)	11 (37.9)	34 (55.7)	440 (53.9)	
Age (year), median (IQR)	54.5 (14.5)	57.0 (21.0)	59.0 (14.0)	54.0 (18.0)	52.5 (26.5)	57.0 (19.0)	0.537
BMI (m/kg <sup>2</sup> ), median (IQR)	25.4 (4.76)	24.3 (5.24)	29.0 (7.08)	24.5 (4.02)	24.9 (6.81)	25.3 (5.86)	<0.001
AST (U/L), median (IQR)	43 (34)	29 (24)	37 (30)	35 (33)	40 (40)	33 (27)	<0.001
ALT (U/L), median (IQR)	32 (24)	30 (30)	37 (36)	28 (31)	44 (42)	32 (33)	0.002
GGT (U/L), median (IQR)	130 (199)	30.0 (49.8)	76.0 (129)	46.0 (245)	95.0 (145)	45.0 (89.0)	<0.001
FIB 4 (points), median (IQR)	3.78 (3.90)	1.66 (1.59)	1.91 (2.30)	1.64 (2.90)	1.78 (3.74)	1.81 (2.26)	<0.001
ALP (U/L), median (IQR)	93 (47)	73 (32)	81 (44)	99 (97)	101 (50)	78 (46)	<0.001
Platelet (g/L), median (IQR)	126 (106)	188 (88.0)	183 (110)	180 (188)	179 (118)	180 (100)	<0.001
Albumin (g/dL), median (IQR)	37.0 (8.0)	44.0 (5.6)	42.0 (6.8)	36.7 (13.4)	40.4 (8.5)	42.5 (8.3)	<0.001
INR, median (IQR)	1.30 (0.48)	1.01 (0.11)	1.10 (0.30)	1.20 (0.48)	1.20 (0.40)	1.10 (0.30)	<0.001
Bilirubin (mg/dL), median (IQR)	1.12 (1.82)	0.63 (0.46)	0.79 (0.74)	1.04 (1.68)	0.78 (1.01)	0.73 (0.65)	<0.001
Cholesterol (mg/dL), median (IQR)	141 (61)	168 (56)	164 (55)	153 (70)	159 (52)	165 (63)	0.040
TE probe							
M	68 (82.9)	440 (85.9)	79 (59.8)	25 (86.2)	52 (85.2)	664 (81.4)	<0.001
XL	14 (17.1)	72 (14.1)	53 (40.2)	4 (13.8)	9 (14.8)	152 (18.6)	
VCTE-LSM (kPa), median (IQR)	27.7 (51.1)	6.7 (6.0)	6.2 (9.6)	15.0 (14.8)	8.8 (11.7)	7.2 (9.1)	<0.001
VCTE-LSM IQR/Med. (%), median (IQR)	12.0 (13.8)	13.0 (9.0)	14.0 (9.3)	13.0 (10.0)	14.5 (8.6)	13.0 (9.0)	0.379
CAP (dB/m), median (IQR)	250 (92)	234 (74)	300 (73)	216 (57)	218 (85)	243 (85)	<0.001
CAP IQR (dB/m), median (IQR)	32 (24)	35 (23)	32 (26)	42 (21)	42 (29)	35 (24)	0.133
ElastQ-LSM median (kPa), median (IQR)	11.7 (11.1)	6.5 (4.3)	6.0 (4.5)	8.4 (6.2)	7.8 (5.6)	6.6 (5.4)	<0.001
ElastQ-LSM IQR/Med. (%), median (IQR)	10.6 (11.5)	9.7 (10.0)	9.8 (10.2)	7.8 (11.4)	11.2 (10.5)	9.8 (10.7)	0.118
Center							
Center 1	5 (6.1)	211 (41.2)	41 (31.1)	7 (24.1)	19 (31.1)	283 (34.7)	<0.001
Center 2	17 (20.7)	157 (30.7)	54 (40.9)	2 (6.9)	7 (11.5)	237 (29.0)	
Center 3	60 (73.2)	144 (28.1)	37 (28.0)	20 (69.0)	35 (57.4)	296 (36.3)	

Values are presented as number (%) unless otherwise indicated.

ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease; AIH, autoimmune hepatitis; IQR, interquartile range; BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine transaminase; GGT, gamma-glutamyl transferase; FIB 4, Fibrosis-4 score; ALP, alkaline phosphatase; INR, international normalized ratio; VCTE, vibration-controlled transient elastography; LSM, liver stiffness measurement; Med., median; CAP, controlled attenuation parameter; dB/m, decibel/meter.

**Supplementary Table 3. Pearson's correlation per etiology**

	ALD (n=82)	Viral hepatitis (n=512)	NAFLD (n=132)	Cholestatic/AIH (n=29)	Other/Cryptogenic (n=60)
Total (%)	10.1	62.7	16.2	3.6	7.4
VCTE-LSM (kPa), median	27.7	6.7	6.15	15.0	8.6
VCTE-LSM >25 kPa, n (%)	43 (52.4)	29 (5.7)	15 (11.4)	5 (17.2)	13 (21.7)
Pearson's R	0.588	0.727	0.540	0.555	0.465

ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease; AIH, autoimmune hepatitis; VCTE, vibration-controlled transient elastography; LSM, liver stiffness measurement.